Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Mar 19;18:1369282. doi: 10.3389/fncel.2024.1369282

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2024 Singh, Randle, Walters and Cox.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

HC loss caused by Pou4f3 deletion does not affect the survival of SCs. (A–D) Representative confocal images of the middle turn from control (A, C) and cochleae with Pou4f3 deletion at P0 using Atoh1-Pou4f3cKO mice (B) or at 8 weeks using Prestin-Pou4f3cKO mice (D). All samples were analyzed at 4 months post-tamoxifen. (E, F) Quantification of SOX2-positive SC nuclei in each cochlear turn for control and after Pou4f3 deletion at P0/P1 (E) or 8 weeks of age (F). SCs numbers were compared to control within the same cochlear turn using a two-way ANOVA followed by Sidak's post-hoc test. There was a significant main effect of genotype [F_(1,6) = 12.93, p = 0.0114] when Pou4f3 was deleted at P0/P1, but there were no main effects when Pou4f3 was deleted at 8 weeks of age and no significant differences in the post-hoc tests for either age of Pou4f3 deletion. N = 3. Scale bar = 20 μm.